🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 01/11/2013 | 70,16 | 70,32 | 66,81 | 67,36 | -5,59% | 5,00% | 3.938.900 |
| 31/10/2013 | 71,75 | 72,38 | 70,25 | 71,35 | -0,56% | 2,97% | 2.462.000 |
| 30/10/2013 | 74,97 | 75,37 | 70,76 | 71,75 | -5,70% | 6,15% | 2.685.100 |
| 29/10/2013 | 76,08 | 76,88 | 72,57 | 76,09 | -2,24% | 5,67% | 3.696.400 |
| 28/10/2013 | 76,67 | 78,01 | 76,21 | 77,83 | +1,30% | 2,35% | 1.449.400 |
| 25/10/2013 | 77,70 | 78,38 | 76,00 | 76,83 | -0,10% | 3,06% | 1.619.500 |
| 24/10/2013 | 75,75 | 77,74 | 75,61 | 76,91 | +1,72% | 2,81% | 1.252.500 |
| 23/10/2013 | 77,10 | 77,98 | 75,26 | 75,61 | -2,59% | 3,53% | 1.737.400 |
| 22/10/2013 | 75,13 | 77,98 | 74,94 | 77,62 | +3,99% | 4,05% | 1.525.300 |
| 21/10/2013 | 77,30 | 77,53 | 74,51 | 74,64 | -3,14% | 3,91% | 1.873.700 |
| 18/10/2013 | 77,08 | 78,00 | 74,96 | 77,06 | +0,26% | 3,94% | 2.234.500 |
| 17/10/2013 | 75,13 | 77,48 | 74,40 | 76,86 | +1,86% | 4,10% | 1.420.800 |
| 16/10/2013 | 74,13 | 75,92 | 73,43 | 75,46 | +2,88% | 3,36% | 1.766.500 |
| 15/10/2013 | 72,49 | 74,15 | 72,42 | 73,35 | -0,49% | 2,39% | 1.994.900 |
| 14/10/2013 | 69,74 | 74,02 | 69,64 | 73,71 | +3,93% | 6,28% | 1.722.700 |
| 11/10/2013 | 70,49 | 71,00 | 68,89 | 70,92 | -0,10% | 2,99% | 1.684.800 |
| 10/10/2013 | 70,12 | 71,61 | 69,45 | 70,99 | +1,20% | 3,08% | 1.537.700 |
| 09/10/2013 | 72,40 | 72,59 | 68,71 | 70,15 | -2,87% | 5,36% | 2.638.900 |
| 08/10/2013 | 75,41 | 75,85 | 71,50 | 72,22 | -4,32% | 5,77% | 2.216.700 |
| 07/10/2013 | 76,05 | 76,32 | 75,07 | 75,48 | -2,24% | 1,64% | 936.100 |
| 04/10/2013 | 77,51 | 77,84 | 76,60 | 77,21 | +0,06% | 1,60% | 1.316.900 |
| 03/10/2013 | 76,75 | 77,65 | 75,92 | 77,16 | +0,55% | 2,25% | 2.017.200 |
| 02/10/2013 | 76,26 | 76,83 | 75,49 | 76,74 | -0,36% | 1,76% | 1.049.300 |
| 01/10/2013 | 76,02 | 77,12 | 74,99 | 77,02 | +1,58% | 2,80% | 1.292.800 |
| 30/09/2013 | 75,32 | 77,20 | 74,97 | 75,82 | -0,37% | 2,96% | 1.277.200 |
| 27/09/2013 | 75,68 | 77,51 | 75,16 | 76,10 | -0,56% | 3,11% | 1.028.600 |
| 26/09/2013 | 74,67 | 76,59 | 74,34 | 76,53 | +2,49% | 3,01% | 1.564.400 |
| 25/09/2013 | 74,55 | 75,71 | 74,44 | 74,67 | +0,19% | 1,70% | 3.181.900 |
| 24/09/2013 | 75,14 | 75,70 | 73,43 | 74,53 | -1,40% | 3,02% | 2.845.200 |
| 23/09/2013 | 76,55 | 76,74 | 74,94 | 75,59 | -0,74% | 2,35% | 3.251.200 |